Developer docs
API playgroundTry for free, no card

Search company profiles

ACA Pharma

Full company profile

uuid0006sn7

Namestring
ACA Pharma
Websiteurl
acapharma.net
Company typeenum
Private
Founded yearint
1997
Descriptiontext

ACA Pharma is a New York-headquartered, privately held specialty pharmaceutical distribution company founded in 1997 that operates as an end-to-end commercialization partner for global pharma manufacturers seeking access to Greater China and Southeast Asia. The company acquires exclusive rights to register and distribute branded, clinically urgent, orphan, and rare-disease drugs, and reaches patients through a curated hospital network anchored by the China NPP Group Procurement program covering 90+ hospitals and approximately 95% of pediatric rare-disease patients in China, plus lighthouse launch centers in Macau and Singapore. Its current portfolio includes Omisirge (FDA-approved cell therapy from Ayrmid Ltd., for hematologic malignancies), RYANODEX and Barhemsys (from Eagle Pharmaceuticals, for malignant hyperthermia and related indications), and Feraheme (from Azurity Pharmaceuticals, for iron-deficiency anemia), with RYANODEX territory expanded in late 2025 into Europe, Latin America, the Middle East, and broader Asia-Pacific.

ACA Pharma monetizes through product-distribution margins on exclusive territory licenses from manufacturer partners and through its role as gatekeeper of prioritized hospital procurement for rare and clinically urgent drugs in Asia-Pacific. Its go-to-market relies on clinician education, professional society partnerships (e.g., the Indian Society of Anaesthesiologists for the Ryanodex India launch), and regulatory navigation — including sequencing launches through fast-track jurisdictions before broader rollout. Pricing is not publicly disclosed; transaction economics are negotiated through hospital procurement programs and country-level regulatory approvals rather than standardized list pricing. Geographic coverage spans at least 15 markets (Mainland China, Hong Kong SAR, Macau SAR, Mongolia, Brunei, Cambodia, Indonesia, Lao PDR, Malaysia, Myanmar, Philippines, Singapore, Thailand, Vietnam, Timor-Leste), with offices in Hong Kong, Macau, Singapore, and Mainland China, and recent extensions into India, Europe, LATAM, and the Middle East.

Short descriptiontext

ACA Pharma is a US-headquartered, privately held specialty pharmaceutical distributor (founded 1997) that holds exclusive Asia-Pacific distribution rights for branded orphan, rare-disease, and specialty drugs, commercializing them through a 90+ hospital network in China and lighthouse centers in Macau and Singapore.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty pharmaceutical distribution, orphan drug distribution, rare disease therapeutics, pharmaceutical licensing, Asia-Pacific market access
Industry4 codes
PRIMARYHLAIAJAB
Specialty Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAGAMAD
Specialty Pharma & Biologics Distribution (GDP-compliant)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Supply Chain, Logistics & Cold Chain for Life Sciences
SECONDARYHLAFALAC
Specialty Pharmacies (Complex/High-Cost Therapies)
Healthcare & Life Sciences/Healthcare Providers & Systems/Pharmacy & Medication Management Services
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code1 code
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Specialty Pharmaceutical Distribution
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Distribution
TypeTransaction Fee
Description

ACA Pharma generates revenue as an exclusive distributor of specialty pharmaceutical products across Asia-Pacific markets. The company acquires exclusive rights to register and distribute innovative drugs, earning margins on product sales through hospital networks and pharmacy channels.

morningstar.com
2Exclusive Licensing Agreements
TypeLicensing Royalties
Description

Revenue derived from exclusive distribution partnerships with global pharmaceutical companies (Eagle Pharmaceuticals, Azurity Pharmaceuticals, Ayrmid Ltd.) for branded specialty medications in defined territories.

prweb.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Supply Chain, Operations, Personnel, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

ACA Pharma operates as an exclusive specialty pharmaceutical distributor that acquires distribution rights from global pharma manufacturers for innovative drugs (orphan drugs, cell therapies, rare-disease treatments) and commercializes them across Asia-Pacific markets. The company leverages fast-track regulatory registration routes, established hospital networks (90+ hospitals in China via the NPP Group Procurement program), and clinician education programs to deliver specialty pharmaceutical products to healthcare providers and patients in 15 markets across Greater China and Southeast Asia.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 95% coverage of pediatric rare disease patients in China through NPP Group Procurement network
+2 more records
Product overview1 text field

ACA Pharma operates as a specialty pharmaceutical distribution company with a portfolio of FDA-approved and clinically urgent drugs. The company functions as exclusive distributor for multiple pharmaceutical products across Asia-Pacific markets, including: Omisirge (cell therapy for hematologic malignancies), RYANODEX (for malignant hyperthermia), Barhemsys (specialty pharmaceutical), and Feraheme (iron replacement therapy). The company also manages the China NPP Group Procurement Program providing prioritized hospital access for orphan and rare-disease drugs. The product portfolio is distributed through exclusive manufacturer partnerships with companies including Ayrmid Ltd., Eagle Pharmaceuticals, and Azurity Pharmaceuticals.

Product and service5 records
1Omisirge
CategoryCell Therapy
Description

FDA-approved cell therapy (Omidubicel-onlv) for hematologic malignancies and severe aplastic anemia, distributed exclusively by ACA Pharma across 15 markets in Greater China and Southeast Asia for healthcare providers treating patients with hematologic malignancies.

2RYANODEX
CategoryEmergency Medicine / Anesthesiology
Description

Drug developed by Eagle Pharmaceuticals for malignant hyperthermia emergency treatment, distributed exclusively by ACA Pharma across Hong Kong, Macau, Singapore, Greater China, and expanded territories in Europe, Latin America, Middle East, and Asia-Pacific.

3Barhemsys
CategorySpecialty Pharmaceutical
Description

Specialty pharmaceutical product distributed by ACA Pharma under exclusive distribution agreement with Eagle Pharmaceuticals across Hong Kong, Macau, Singapore, and Greater China for healthcare providers.

4Feraheme
CategoryIron Replacement Therapy
Description

Intravenous iron replacement therapy for iron deficiency anemia, distributed exclusively by ACA Pharma in Hong Kong, Macau, Greater Bay Area, Mainland China, and Singapore under partnership with Azurity Pharmaceuticals.

5China NPP Group Procurement Program
CategoryHospital Access Program
Description

Prioritized access program for orphan, pediatric rare-disease, and clinically urgent drugs operated through a network of over 90 hospitals in China covering approximately 95% of pediatric rare disease patients.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-09
Description

ACA Pharma appointed as exclusive distributor for Omisirge (FDA-approved cell therapy) across 15 markets in Greater China and Southeast Asia, covering Mainland China, Hong Kong SAR, Macau SAR, Mongolia, Brunei, Cambodia, Indonesia, Lao PDR, Malaysia, Myanmar, Philippines, Singapore, Thailand, Vietnam, and Timor-Leste. ACA Pharma holds exclusive rights to register and distribute the therapy, with initial lighthouse centers planned in Macau and Singapore before expanding to additional jurisdictions.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2025-11-20
Description

Professional medical society partnership hosting virtual nationwide launch of Ryanodex in India to improve emergency response to malignant hyperthermia. Eagle Pharmaceuticals (manufacturer) and ACA Pharma (distribution partner) collaborated with the society for this launch event.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-10-23
Description

ACA Pharma and Azurity Pharmaceuticals announced exclusive distribution partnership for Feraheme (intravenous iron replacement therapy) in Hong Kong, Macau, Greater Bay Area, Mainland China, and Singapore. Feraheme is used for iron deficiency anemia, which is widespread in the region.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-10-09
Description

ACA Pharma signed exclusive distribution agreement with Eagle Pharmaceuticals to commercialize Ryanodex and Barhemsys across Hong Kong, Macau, Singapore, and Greater China. Products have completed or are progressing in regulatory approval processes, with plans for expansion into Latin America, Europe, and other areas. Also expanded territory for RYANODEX distribution across Europe, Latin America, Middle East, and Asia-Pacific.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1McKesson
TypeBroad incumbent
Description

One of the largest pharmaceutical distributors globally with operations in North America and Europe. Comparable at the level of specialty pharmaceutical distribution infrastructure, but operates as a broad incumbent rather than a focused Asia-Pacific commercialization partner.

TypeDirect peer
Description

Swiss-listed market expansion services company that helps pharmaceutical, consumer, and specialty product companies grow in Asia. Directly comparable as an Asia-focused commercialization and distribution partner with similar exclusive-agreement-driven business model for healthcare clients.

TypeDirect peer
Description

Specialty logistics and distribution arm of Cencora focused on cell and gene therapies, orphan drugs, and time/temperature-sensitive pharmaceuticals. Highly comparable to ACA Pharma's specialty distribution focus on cell therapies (Omisirge) and rare disease drugs across multiple jurisdictions.

TypeDirect peer
Description

Thailand-headquartered pharma distribution and marketing company focused on emerging Asia-Pacific markets. Comparable in serving as a regional commercialization partner for international specialty and branded pharmaceutical manufacturers.

TypeBroad incumbent
Description

Global logistics provider with a dedicated Life Sciences & Healthcare division offering GDP-compliant pharma distribution, cold chain, and clinical trial logistics. Overlapping capability with ACA Pharma's specialty pharma and biologics distribution, though DHL operates as a broader portfolio logistics player rather than a focused commercial distributor.

TypeDirect peer
Description

One of the largest healthcare distribution companies in Asia-Pacific, providing pharma distribution, market access, and patient-centric services across 16+ markets. Closest comparable to ACA Pharma in business model (specialty pharma distribution for innovator manufacturers) and geographic footprint (Greater China and Southeast Asia).

7Shanghai Pharmaceuticals Holding
TypeRegional player
Description

One of China's largest pharmaceutical distribution and manufacturing groups, listed in Hong Kong and Shanghai. Regional comparable for ACA Pharma's China-centric hospital distribution and procurement programs, though it operates as a domestic incumbent at much larger scale.

TypeBroad incumbent
Description

Major U.S.-based pharmaceutical distributor with global reach including specialty distribution capabilities. Broad incumbent peer for ACA Pharma's specialty pharma distribution model, though Cardinal Health primarily serves U.S. and select international markets rather than Asia-Pacific-focused distribution.

9TransAsian Pharma / Bharat Serums and Vaccines (Asia arm)
TypeEmerging player
Description

Specialty pharmaceutical companies expanding distribution partnerships for branded and complex-therapy products across Asia. Comparable as smaller specialty distributors leveraging exclusive partnerships to commercialize innovator products in emerging Asian markets.

TypeBroad incumbent
Description

Top-tier global pharmaceutical distributor with significant specialty pharma, animal health, and global commercialization services (through PharmaLex and World Courier). Comparable in serving specialty and orphan drug manufacturers with distribution and market access services, though at much greater scale and global reach than ACA Pharma.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ACA Pharma

Specialty Pharmaceutical Distributionacapharma.net

ACA Pharma is a US-headquartered, privately held specialty pharmaceutical distributor (founded 1997) that holds exclusive Asia-Pacific distribution rights for branded orphan, rare-disease, and specialty drugs, commercializing them through a 90+ hospital network in China and lighthouse centers in Macau and Singapore.

What ACA Pharma does

ACA Pharma is a New York-headquartered, privately held specialty pharmaceutical distribution company founded in 1997 that operates as an end-to-end commercialization partner for global pharma manufacturers seeking access to Greater China and Southeast Asia. The company acquires exclusive rights to register and distribute branded, clinically urgent, orphan, and rare-disease drugs, and reaches patients through a curated hospital network anchored by the China NPP Group Procurement program covering 90+ hospitals and approximately 95% of pediatric rare-disease patients in China, plus lighthouse launch centers in Macau and Singapore. Its current portfolio includes Omisirge (FDA-approved cell therapy from Ayrmid Ltd., for hematologic malignancies), RYANODEX and Barhemsys (from Eagle Pharmaceuticals, for malignant hyperthermia and related indications), and Feraheme (from Azurity Pharmaceuticals, for iron-deficiency anemia), with RYANODEX territory expanded in late 2025 into Europe, Latin America, the Middle East, and broader Asia-Pacific.

ACA Pharma monetizes through product-distribution margins on exclusive territory licenses from manufacturer partners and through its role as gatekeeper of prioritized hospital procurement for rare and clinically urgent drugs in Asia-Pacific. Its go-to-market relies on clinician education, professional society partnerships (e.g., the Indian Society of Anaesthesiologists for the Ryanodex India launch), and regulatory navigation — including sequencing launches through fast-track jurisdictions before broader rollout. Pricing is not publicly disclosed; transaction economics are negotiated through hospital procurement programs and country-level regulatory approvals rather than standardized list pricing. Geographic coverage spans at least 15 markets (Mainland China, Hong Kong SAR, Macau SAR, Mongolia, Brunei, Cambodia, Indonesia, Lao PDR, Malaysia, Myanmar, Philippines, Singapore, Thailand, Vietnam, Timor-Leste), with offices in Hong Kong, Macau, Singapore, and Mainland China, and recent extensions into India, Europe, LATAM, and the Middle East.

ACA Pharma firmographics

Firmographics
Name
ACA Pharma
Website
https://acapharma.net
Company type
Private
Founded year
1997
Operating status
Operating
Headcount range
1–10 employees
Short description
ACA Pharma is a US-headquartered, privately held specialty pharmaceutical distributor (founded 1997) that holds exclusive Asia-Pacific distribution rights for branded orphan, rare-disease, and specialty drugs, commercializing them through a 90+ hospital network in China and lighthouse centers in Macau and Singapore.
Ownership category
akta.pro rank

ACA Pharma industry classification

Industry
Product category
Specialty Pharmaceutical Distribution
NAICS
Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIAJAB
Specialty Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAGAMAD
Specialty Pharma & Biologics Distribution (GDP-compliant)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Supply Chain, Logistics & Cold Chain for Life Sciences
SECONDARYHLAFALAC
Specialty Pharmacies (Complex/High-Cost Therapies)
Healthcare & Life Sciences/Healthcare Providers & Systems/Pharmacy & Medication Management Services
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Specialty pharmaceutical distribution
  • Orphan drug distribution
  • Rare disease therapeutics
  • Pharmaceutical licensing
  • Asia-Pacific market access

Where ACA Pharma is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices4 records

Markets served

ACA Pharma business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Supply Chain, Operations, Personnel, Marketing or Sales

Revenue model

  1. Pharmaceutical Distribution: ACA Pharma generates revenue as an exclusive distributor of specialty pharmaceutical products across Asia-Pacific markets. The company acquires exclusive rights to register and distribute innovative drugs, earning margins on product sales through hospital networks and pharmacy channels.
  2. Exclusive Licensing Agreements: Revenue derived from exclusive distribution partnerships with global pharmaceutical companies (Eagle Pharmaceuticals, Azurity Pharmaceuticals, Ayrmid Ltd.) for branded specialty medications in defined territories.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

ACA Pharma product offering

Product offering

Core offering

ACA Pharma operates as an exclusive specialty pharmaceutical distributor that acquires distribution rights from global pharma manufacturers for innovative drugs (orphan drugs, cell therapies, rare-disease treatments) and commercializes them across Asia-Pacific markets. The company leverages fast-track regulatory registration routes, established hospital networks (90+ hospitals in China via the NPP Group Procurement program), and clinician education programs to deliver specialty pharmaceutical products to healthcare providers and patients in 15 markets across Greater China and Southeast Asia.

Product overview

ACA Pharma operates as a specialty pharmaceutical distribution company with a portfolio of FDA-approved and clinically urgent drugs. The company functions as exclusive distributor for multiple pharmaceutical products across Asia-Pacific markets, including: Omisirge (cell therapy for hematologic malignancies), RYANODEX (for malignant hyperthermia), Barhemsys (specialty pharmaceutical), and Feraheme (iron replacement therapy). The company also manages the China NPP Group Procurement Program providing prioritized hospital access for orphan and rare-disease drugs. The product portfolio is distributed through exclusive manufacturer partnerships with companies including Ayrmid Ltd., Eagle Pharmaceuticals, and Azurity Pharmaceuticals.

Differentiator

Problem solved

Functional benefit

Products and services

  • Omisirge FDA-approved cell therapy (Omidubicel-onlv) for hematologic malignancies and severe aplastic anemia, distributed exclusively by ACA Pharma across 15 markets in Greater China and Southeast Asia for healthcare providers treating patients with hematologic malignancies.
  • RYANODEX Drug developed by Eagle Pharmaceuticals for malignant hyperthermia emergency treatment, distributed exclusively by ACA Pharma across Hong Kong, Macau, Singapore, Greater China, and expanded territories in Europe, Latin America, Middle East, and Asia-Pacific.
  • Barhemsys Specialty pharmaceutical product distributed by ACA Pharma under exclusive distribution agreement with Eagle Pharmaceuticals across Hong Kong, Macau, Singapore, and Greater China for healthcare providers.
  • Feraheme Intravenous iron replacement therapy for iron deficiency anemia, distributed exclusively by ACA Pharma in Hong Kong, Macau, Greater Bay Area, Mainland China, and Singapore under partnership with Azurity Pharmaceuticals.
  • China NPP Group Procurement Program Prioritized access program for orphan, pediatric rare-disease, and clinically urgent drugs operated through a network of over 90 hospitals in China covering approximately 95% of pediatric rare disease patients.

Quantifiable outcome

  • 95% coverage of pediatric rare disease patients in China through NPP Group Procurement network
  • +2 more outcomes

Companies that use ACA Pharma

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles2 records

ACA Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

ACA Pharma partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • Ayrmid Ltd. (parent of Gamida Cell Inc.)coreChannel Partner/ Reseller/ Distributor · 9 February 2026ACA Pharma appointed as exclusive distributor for Omisirge (FDA-approved cell therapy) across 15 markets in Greater China and Southeast Asia, covering Mainland China, Hong Kong SAR, Macau SAR, Mongolia, Brunei, Cambodia, Indonesia, Lao PDR, Malaysia, Myanmar, Philippines, Singapore, Thailand, Vietnam, and Timor-Leste. ACA Pharma holds exclusive rights to register and distribute the therapy, with initial lighthouse centers planned in Macau and Singapore before expanding to additional jurisdictions.
  • Indian Society of AnaesthesiologistsminorGTM or Marketing Partner · 20 November 2025Professional medical society partnership hosting virtual nationwide launch of Ryanodex in India to improve emergency response to malignant hyperthermia. Eagle Pharmaceuticals (manufacturer) and ACA Pharma (distribution partner) collaborated with the society for this launch event.
  • Azurity PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 23 October 2025ACA Pharma and Azurity Pharmaceuticals announced exclusive distribution partnership for Feraheme (intravenous iron replacement therapy) in Hong Kong, Macau, Greater Bay Area, Mainland China, and Singapore. Feraheme is used for iron deficiency anemia, which is widespread in the region.
  • Eagle PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 9 October 2025ACA Pharma signed exclusive distribution agreement with Eagle Pharmaceuticals to commercialize Ryanodex and Barhemsys across Hong Kong, Macau, Singapore, and Greater China. Products have completed or are progressing in regulatory approval processes, with plans for expansion into Latin America, Europe, and other areas. Also expanded territory for RYANODEX distribution across Europe, Latin America, Middle East, and Asia-Pacific.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

ACA Pharma competitors and assessment

Company assessment

Broad incumbents

  • McKesson: One of the largest pharmaceutical distributors globally with operations in North America and Europe. Comparable at the level of specialty pharmaceutical distribution infrastructure, but operates as a broad incumbent rather than a focused Asia-Pacific commercialization partner.
  • DHL Supply Chain (Life Sciences & Healthcare): Global logistics provider with a dedicated Life Sciences & Healthcare division offering GDP-compliant pharma distribution, cold chain, and clinical trial logistics. Overlapping capability with ACA Pharma's specialty pharma and biologics distribution, though DHL operates as a broader portfolio logistics player rather than a focused commercial distributor.
  • Cardinal Health: Major U.S.-based pharmaceutical distributor with global reach including specialty distribution capabilities. Broad incumbent peer for ACA Pharma's specialty pharma distribution model, though Cardinal Health primarily serves U.S. and select international markets rather than Asia-Pacific-focused distribution.
  • Cencora (AmerisourceBergen): Top-tier global pharmaceutical distributor with significant specialty pharma, animal health, and global commercialization services (through PharmaLex and World Courier). Comparable in serving specialty and orphan drug manufacturers with distribution and market access services, though at much greater scale and global reach than ACA Pharma.

Direct peers

  • DKSH Holding: Swiss-listed market expansion services company that helps pharmaceutical, consumer, and specialty product companies grow in Asia. Directly comparable as an Asia-focused commercialization and distribution partner with similar exclusive-agreement-driven business model for healthcare clients.
  • World Courier (Cencora): Specialty logistics and distribution arm of Cencora focused on cell and gene therapies, orphan drugs, and time/temperature-sensitive pharmaceuticals. Highly comparable to ACA Pharma's specialty distribution focus on cell therapies (Omisirge) and rare disease drugs across multiple jurisdictions.
  • Mega Lifesciences: Thailand-headquartered pharma distribution and marketing company focused on emerging Asia-Pacific markets. Comparable in serving as a regional commercialization partner for international specialty and branded pharmaceutical manufacturers.
  • Zuellig Pharma: One of the largest healthcare distribution companies in Asia-Pacific, providing pharma distribution, market access, and patient-centric services across 16+ markets. Closest comparable to ACA Pharma in business model (specialty pharma distribution for innovator manufacturers) and geographic footprint (Greater China and Southeast Asia).

Regional players

  • Shanghai Pharmaceuticals Holding: One of China's largest pharmaceutical distribution and manufacturing groups, listed in Hong Kong and Shanghai. Regional comparable for ACA Pharma's China-centric hospital distribution and procurement programs, though it operates as a domestic incumbent at much larger scale.

Emerging players

  • TransAsian Pharma / Bharat Serums and Vaccines (Asia arm): Specialty pharmaceutical companies expanding distribution partnerships for branded and complex-therapy products across Asia. Comparable as smaller specialty distributors leveraging exclusive partnerships to commercialize innovator products in emerging Asian markets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

ACA Pharma social profiles

Digital presence

ACA Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ACA Pharma leadership team

Management profile

Number of profiles

ACA Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ACA Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ACA Pharma

What does ACA Pharma do?

ACA Pharma operates as an exclusive specialty pharmaceutical distributor that acquires distribution rights from global pharma manufacturers for innovative drugs (orphan drugs, cell therapies, rare-disease treatments) and commercializes them across Asia-Pacific markets. The company leverages fast-track regulatory registration routes, established hospital networks (90+ hospitals in China via the NPP Group Procurement program), and clinician education programs to deliver specialty pharmaceutical products to healthcare providers and patients in 15 markets across Greater China and Southeast Asia.

Is ACA Pharma a public or private company?

ACA Pharma is a private company. It is classified as unknown and is currently operating.

When was ACA Pharma founded?

ACA Pharma was founded in 1997. It employs 1 to 10 people.

Where is ACA Pharma based?

ACA Pharma is headquartered in New York, United States, in the North America region.

How does ACA Pharma make money?

Two revenue lines are on record. Pharmaceutical Distribution is the primary driver. The others are exclusive Licensing Agreements.

Who are ACA Pharma's main competitors?

Broad incumbents on record are McKesson, DHL Supply Chain (Life Sciences & Healthcare), Cardinal Health and Cencora (AmerisourceBergen). Direct peers are DKSH Holding, World Courier (Cencora), Mega Lifesciences and Zuellig Pharma. Shanghai Pharmaceuticals Holding is listed as a regional player. TransAsian Pharma / Bharat Serums and Vaccines (Asia arm) is listed as an emerging player.

Does ACA Pharma have an API?

No public API is recorded for ACA Pharma.

What industry is ACA Pharma in?

ACA Pharma's product category is Specialty Pharmaceutical Distribution. Its primary akta.pro industry code is HLAIAJAB, Specialty Pharmaceutical Distributors, with a secondary code of HLAGAMAD, Specialty Pharma & Biologics Distribution (GDP-compliant). Its NAICS code is 424210 and its SIC code is 5122.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireACA Pharma and Azurity Pharmaceuticals Announce Approval of Feraheme® and Ferabright™ in MacauACA Pharma and Azurity Pharmaceuticals announced regulatory approval of Feraheme and Ferabright in Macau, with Feraheme approved on April 2, 2026 and Ferabright on May 13, 2026. The approvals support expanding access to ferumoxytol-based products across Asia, and the companies are advancing hospital engagement for potential participation in the Guangdong-Hong Kong-Macao Greater Bay Area pilot zone.PharmiWeb.comAyrmid Appoints ACA Pharma as Exclusive Distributor for Omisirge(R) across Greater China and Southeast AsiaAyrmid Ltd., parent company of Gamida Cell Inc., has appointed ACA Pharma as the exclusive distributor for its FDA-approved cell therapy Omisirge (Omidubicel-onlv) across 15 markets in Greater China and Southeast Asia, including Mainland China, Hong Kong, Singapore, Vietnam, and Indonesia. Under the agreement, ACA Pharma holds exclusive rights to register and distribute the therapy, with initial lighthouse centers planned in Macau and Singapore before expanding to additional jurisdictions. The partnership enables Ayrmid to expand patient access for Omisirge, which is approved in the United States for hematologic malignancies and severe aplastic anemia, while leveraging ACA Pharma's fast-track registration capabilities in the region.BioSpaceAyrmid Appoints ACA Pharma as Exclusive Distributor for Omisirge(R) across Greater China and Southeast AsiaAyrmid Ltd., the parent company of Gamida Cell Inc., has appointed ACA Pharma as the exclusive distributor for its FDA-approved cell therapy Omisirge across 15 markets in Greater China and Southeast Asia, including Mainland China, Hong Kong SAR, Macau SAR, Singapore, Vietnam, and Indonesia. Under the agreement, ACA Pharma receives exclusive rights to register and distribute Omisirge, with initial launch efforts focused on lighthouse centers in Macau and Singapore. Omisirge is approved in the United States for use in adult and pediatric patients with hematologic malignancies or severe aplastic anemia undergoing cord blood transplantation.MorningstarAyrmid Appoints ACA Pharma as Exclusive Distributor for Omisirge(R) across Greater China and Southeast AsiaAyrmid Ltd. has appointed ACA Pharma as the exclusive distributor for its FDA-approved cell therapy Omisirge across 15 markets in Greater China and Southeast Asia, covering Mainland China, Hong Kong SAR, Macau SAR, Mongolia, Brunei, Cambodia, Indonesia, Lao PDR, Malaysia, Myanmar, Philippines, Singapore, Thailand, Vietnam, and Timor-Leste. Under the agreement, ACA Pharma holds exclusive rights to register and distribute Omisirge, with initial launch efforts focused on lighthouse centers in Macau and Singapore before expanding to other jurisdictions. The therapy is approved in the United States for adult and pediatric patients with hematologic malignancies and severe aplastic anemia.EIN PresswireACA Pharma Announces Major Expansion of RYANODEX® Territory Outside the United StatesACA Pharma announced a significant expansion of its exclusive distribution territory for RYANODEX® (dantrolene sodium), a treatment for malignant hyperthermia, extending beyond its previous Asia-focused markets to now cover the majority of Europe, Latin America, the Middle East, and Asia-Pacific. Eagle Pharmaceuticals, the developer and manufacturer of Ryanodex®, has entrusted ACA Pharma as its primary distribution partner for these new markets. The company will be working with hospital systems, anesthesiology societies, and regional partners to support registration, clinician education, and reliable supply across the expanded territory.PrwebACA Pharma Announces 2026 China NPP Group Procurement Priority List for Orphan and Clinically Urgent DrugsACA Pharma announced the launch of its 2026 China NPP Group Procurement Priority List, a multi-hospital request list identifying orphan drugs, pediatric rare-disease therapies, and clinically urgent medicines as highest priority for accelerated access in China. The list covers approximately 95% of all pediatric rare disease patients through a hospital alliance spanning 44 pediatric hospitals, 45 Greater Bay Area hospitals, and top rare-disease centers in Beijing, Shanghai, Tianjin, Chongqing, and Hainan. Global manufacturers can use this coordinated group request system to access fast-track registration routes through China Group NPP and Macau's 30–90 day registration pathway.PrwebACA Pharma Named Exclusive Distributor for Ryanodex® and Barhemsys® in Hong Kong, Macau, Singapore, and Greater ChinaACA Pharma has signed an exclusive distribution agreement with Eagle Pharmaceuticals to commercialize Ryanodex (dantrolene sodium for injection) and Barhemsys (amisulpride injection) across Hong Kong, Macau, Singapore, and Greater China. ACA Pharma has already completed fast-track registration in Macau for Ryanodex and is proceeding with filings in Hong Kong and Singapore, while pursuing national registration in China through the Center for Drug Evaluation and Hainan's Urgently Needed Clinical Medicines List. The agreement positions both FDA-approved hospital products for broader global expansion into Latin America, Asia, Europe, and other unregistered regions through ACA Pharma's established regulatory pathways.